Research has found that diabetes drugs in the U.S. are significantly more expensive compared to other high-income countries. The study suggests that a simple change, such as robust generic competition, could lower prices significantly. For example, the cost of producing a generic vial of insulin could be 97% less than the current market price in the U.S. Similarly, the cost of producing GLP-1 biosimilars could also be much lower. The study calls for policymakers to address the issue of high drug prices, not only in the U.S. but globally, to ensure that life-saving medications are accessible to those who need them.
Source link
GLP-1 generics could be cheaper than Ozempic but still profitable
